Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol in COPD
NCT00794157Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoint: Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at 12 weeks. Started Nov 2008; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00794157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00794157.